Thymosin Alpha-1
Approved as Zadaxin in over 35 countries. One of the most extensive clinical research bodies in immune support.
Mechanism of Action
Bioregulator compound with targeted biochemical activity.
Evidence Chain
Thymosin Alpha-1
COMPOUND
1 Research Goal
• Immune & Antimicrobial
Evidence Strength
2 articles sourced
Knowledge Graph
(3 connections)Research Evidence
(2)Thymosin Alpha-1 and Immune Cell Maturation
Review of Thymosin Alpha-1 mechanisms in T-cell maturation and immune signaling.
Peptide Synergy: Immune System Modulation
Evidence-based review of immune peptide synergy, examining thymic function, antimicrobial defense, and cytokine modulation.
Overview
Thymosin Alpha-1 (Talpha1) is a 28-amino-acid peptide originally isolated from thymosin fraction 5, an extract of calf thymus tissue. Approved as a pharmaceutical under the brand name Zadaxin in over 35 countries (though not in the United States), Thymosin Alpha-1 has one of the most extensive clinical research bodies of any immune-modulating peptide, with applications spanning viral hepatitis, cancer immunotherapy, and infectious disease.
Mechanism of Action
Thymosin Alpha-1 modulates the immune system through multiple mechanisms. It promotes the maturation and differentiation of T lymphocytes, enhances T-cell function, and stimulates the production of cytokines including interferon-alpha, interleukin-2, and interleukin-7. It also enhances the activity of natural killer (NK) cells and dendritic cells. Talpha1 has been shown to modulate the Toll-like receptor (TLR) signaling pathway, enhancing innate immune responses. These immunomodulatory effects make it valuable in conditions characterized by immune dysfunction or deficiency.
Research Highlights
Clinical studies have established Thymosin Alpha-1's efficacy in chronic hepatitis B and C, where it has been used as both monotherapy and in combination with interferon. Research has explored its potential as an adjunct in cancer immunotherapy, with studies in melanoma, hepatocellular carcinoma, and lung cancer. Studies have investigated its use in sepsis, HIV/AIDS, and as an immune adjuvant in vaccination. During the COVID-19 pandemic, Thymosin Alpha-1 was studied as a potential treatment for severe respiratory infections, with some studies suggesting benefits in reducing mortality in critically ill patients.
Dosage & Administration
In clinical practice (where approved), Thymosin Alpha-1 is administered via subcutaneous injection at doses of 1.6 mg, typically 1-2 times weekly. Treatment courses vary by indication, ranging from weeks to months. For research use only (RUO).
Safety Profile
Thymosin Alpha-1 has been used clinically in over 35 countries with a well-established safety profile. Adverse effects are rare and mild, including occasional injection site reactions and transient discomfort. No significant systemic adverse effects have been reported at therapeutic doses. Not approved by the FDA in the United States.
References
King R, et al. Thymosin alpha-1: a clinical update. Ann N Y Acad Sci. 2010. Romanyuk VA, et al. Thymosin alpha-1 in hepatitis. Expert Opin Biol Ther. 2012. Garaci E, et al. Thymosin alpha-1 in cancer. Expert Opin Biol Ther. 2015. All content is for educational and research purposes only.
FDA 2026 Regulatory Update
As of April–June 2026, this compound was among the 14 peptides formally removed from the FDA's Category 2 restricted compounding list following review by the Pharmacy Compounding Advisory Committee (PCAC). This regulatory shift permits licensed compounding pharmacies to produce and dispense this compound under appropriate oversight, subject to final 503A Bulks List adjudication expected following the July 23–24, 2026 PCAC meeting. This does not constitute FDA approval for therapeutic use. All information on this page is for research purposes only.
Related Compounds
Synergy & Compatibility
(3)Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.
View full comparison matrixComputational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.
Community Observations
(0)Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.
No approved observations yet. Sign in to contribute.
For research use only. Not medical advice.